TriangleDISEASE & TREATMENT SETTING
Eloxatin: metastatic Rectal Carcinoma (first-line)
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
In combination with infusional 5-FU/LV for metastatic color or rectal carcinoma that progressed during or within 6 months of completion of first-line therapy with bolus 5 -FU/LV and irinotectan
Broader topic: Rectal Cancer
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- first-line
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Eloxatin (oxaliplatin) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
- source wording
- In combination with infusional 5-FU/LV for metastatic color or rectal carcinoma that progressed during or within 6 months of completion of first-line therapy with bolus 5 -FU/LV and irinotectan
Study evidence for this setting
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice